The Annual Meeting of the Organ Transplantation Branch of the Chinese Medical Association was held! Zhenhealth Medical (02697)'s organ perfusion system was featured in an expert academic report.

On October 15, the 31st Annual Meeting of the Organ Transplantation Branch of the Chinese Medical Association opened in Zhengzhou. During the conference, relevant experts delivered special academic reports on research related to xenogeneic extracorporeal liver support and transplantation. Among them, two studies were carried out relying on the organ perfusion system independently developed by Zhenhealth Medical (02697), focusing respectively on extracorporeal liver cross-circulation and orthotopic whole-liver xenotransplantation in non-human primates. Zhenhealth Medical's organ perfusion system provided the equipment platform for both studies. According to the expert reports, during the experiments the animals' vital signs remained stable, the donor liver continuously secreted bile, and core biochemical indicators were generally stable, effectively compensating for the liver's physiological functions; the body's immune rejection response was controllable, with no hyperacute or acute rejection injury observed, effectively overcoming the core technical challenges of xenogeneic liver transplantation. These results strongly confirm the feasibility and safety of gene-edited pig extracorporeal liver cross-circulation technology for bridging therapy in liver failure, marking a new stage in China's clinical translation research on xenogeneic organ transplantation and providing a completely new technical pathway for the treatment of patients with acute/acute-on-chronic liver failure. Previously, Zhenhealth Medical announced that the company, together with a scientific research team, relying on its independently developed organ perfusion system, had completed preclinical experiments of extracorporeal cross-perfusion support therapy using gene-edited pig livers to assist non-human primate acute liver failure models in six cases, setting a record of stable liver function perfusion support therapy lasting up to 144 hours, with all six cases exceeding 72 hoursthe world's first long-duration efficacy validation of this technology. It is understood that Zhenhealth Medical's organ perfusion system adopts a universal core main unit, paired with replaceable dedicated tubing, organ chambers, perfusion fluids and other consumables and configuration modules, allowing research applications related to normothermic perfusion preservation and extracorporeal life support for multiple organs such as liver, kidney, heart, and lung without replacing the main unit. The announcement stated that the relevant technology is expected in the future to be explored for application in various severe liver dysfunction-related diseases and clinical scenarios, including acute liver failure, subacute liver failure, acute-on-chronic liver failure, severe liver function decompensation and related severe liver diseases, critically ill patients awaiting liver transplantation, and severe liver dysfunction after liver transplantation. The relevant applications are currently exploratory research directions and are not approved clinical indications. Acute liver failure progresses rapidly with a high mortality rate. Existing artificial liver support technologies are still unable to fully replace the liver's complex physiological functions, while liver transplantation is limited by factors such as donor liver resources, patient condition, and transplantation timing, leaving a clinical lack of effective emergency bridging treatment options. The above research explores precisely the use of an extracorporeal perfusion system to connect to an isolated liver with biological activity, achieving potential liver function support and buying a window of time for critically ill liver failure patients to recover liver function or receive a liver transplant.